New here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Zydus, one of India's largest drugmakers, now owns a U.S. cancer-care drug. On June 16, 2026, it finished buying Assertio Holdings for $23.50 a share in cash, a deal worth about $166 million.
The purchase caps a year in which Zydus spent heavily to move from low-margin generics into branded U.S. medicines. It won Assertio only after topping two rival offers, a sign of how hard Indian firms are now pushing to own American drug brands.
Why it matters
An Indian generics maker now controls a U.S. cancer-support drug, part of a wave deciding who owns America's specialty medicines.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
One of India's largest drugmakers, shifting from generics into branded and specialty medicines.
A small U.S. specialty drugmaker built around Rolvedon, a chemotherapy supportive-care medicine.
The rival buyer whose Assertio deal was outbid by Zydus.
Timeline
June 2025 June 2026
-
Zydus completes the takeover
Latest Money MovesThe tender offer closes and Assertio becomes a wholly owned Zydus subsidiary, adding a U.S. oncology drug to its portfolio.
-
Tender offer launched
LegalZydus launches its cash tender offer for all outstanding Assertio shares through a U.S. subsidiary.
-
Zydus tops the bid and wins
Money MovesZydus offers $23.50 a share in all cash. Assertio's board calls it superior and terminates the Garda agreement.
-
Garda raises its bid
Money MovesGarda lifts its offer to $21.80 a share, a 21% jump from its first price, to keep the deal.
-
Assertio agrees to sell to Garda
Money MovesAssertio's board agrees to a takeover by Garda Therapeutics, setting off a contest for the company.
-
Agenus deal clears U.S. security review
RegulatoryZydus completes the Agenus plant purchase after clearance from the Committee on Foreign Investment in the United States.
-
Zydus targets U.S. biologics plants
Money MovesZydus announces a plan to buy two California biologics manufacturing sites from Agenus, its first step into U.S. production.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Sun Pharma buys Ranbaxy (2014)
Sun Pharmaceutical agreed to buy troubled rival Ranbaxy in a $4 billion all-stock deal. The merger created India's largest drugmaker and one of the world's biggest generics players.
Sun absorbed Ranbaxy's plants and pipeline despite ongoing U.S. quality problems at some sites.
It cemented a model of Indian firms scaling up through acquisition rather than slow organic growth.
It set the template Zydus is following: grow abroad by buying, not building.
Lupin buys Gavis Pharmaceuticals (2015)
India's Lupin paid about $880 million for U.S. specialty and generics maker Gavis. The deal handed Lupin a New Jersey base and a pipeline of niche American drug filings.
Lupin gained a direct U.S. commercial and manufacturing foothold.
The bet drew mixed results as U.S. generic prices fell, showing the risk in these platform deals.
It shows both the appeal and the danger of buying a U.S. drug platform for access to the market.
Sun Pharma buys Concert Pharmaceuticals (2023)
Sun Pharma acquired U.S. biotech Concert for up to $576 million to gain an experimental hair-loss drug. The deal pushed Sun deeper into branded specialty medicine.
Sun added a late-stage branded asset to its specialty pipeline.
It marked Indian generics leaders moving up into higher-margin branded U.S. products.
Like Zydus, an Indian generics giant paid up for a branded U.S. specialty drug to escape thin generic margins.
